Enmai Biotechnology
Latest round
- Series A
Last raised
- Feb 2026
Total raised
- Undisclosed
Investors
- 2
About Enmai Biotechnology
, trading as Enmai Biotechnology, is an innovative drug developer that develops innovative clinical diagnostic reagents and antibody drugs based on antibody technology, focusing on the integrated precision diagnosis and treatment of sepsis, viral infections, and autoimmune diseases. The company focuses on the research and development of innovative and precision diagnostic technologies for infectious and chronic inflammatory diseases. Its main products include precision diagnostic kits for sepsis, antibody drugs, and innovative diagnostic and treatment solutions. The company’s revenue is generated by providing drugs for infectious and chronic diseases.
Who invested in Enmai Biotechnology
2 investors across 1 round
See all investors in Enmai Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 24, 2026
Amount
Undisclosed
Investors
Questions about Enmai Biotechnology
Who invested in Enmai Biotechnology?
Enmai Biotechnology has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Enmai Biotechnology raised?
Enmai Biotechnology has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Enmai Biotechnology last raise money?
Enmai Biotechnology's most recent round on record is a Series A, in Feb 2026.
What does Enmai Biotechnology do?
, trading as Enmai Biotechnology, is an innovative drug developer that develops innovative clinical diagnostic reagents and antibody drugs based on antibody technology, focusing on the integrated precision diagnosis and treatment of sepsis, viral infections, and autoimmune diseases.
Where is Enmai Biotechnology headquartered?
Enmai Biotechnology is headquartered in Guangzhou, China.
Which VCs invest in companies like Enmai Biotechnology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Enmai Biotechnology's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Enmai Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.